Acute pain

Dr Joseph Okai, MD Joins Lifestream Health

Retrieved on: 
Monday, September 6, 2021
Pain, Branches of biology, Nervous system, Nociception, Acute pain, Pain management, Chronic pain, Anesthesiology, Neuromodulation, Draft:John Markman

BOWIE, Md., Sept. 6, 2021 /PRNewswire-PRWeb/ --Dr. Joseph Okai is originally from Laurel, Maryland.

Key Points: 
  • BOWIE, Md., Sept. 6, 2021 /PRNewswire-PRWeb/ --Dr. Joseph Okai is originally from Laurel, Maryland.
  • Dr. Okai utilizes a multidisciplinary approach to treating pain which appreciates that both physical and emotional health are both vital to the outcomes of his patients.
  • Dr. Okai joined the Lifestream team after the completion of his training and he is excited about the opportunity to treat the members of the community that he considers his home.
  • Lifestream Health Center has been serving the Bowie/Baltimore-Washington D.C. Metropolitan area since 2000, when the practice was established by Dr. Robert Lyles.

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Medical emergencies, Acute pain, Traumatology, Vesicles, Cells, Extracellular vesicle, Vesicle, Major trauma, Coagulopathy, Injury, Shock

LOS ANGELES, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, “Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic” was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).

Key Points: 
  • The publication titled, Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).
  • The military continues to look for therapeutics that can be delivered in the field to stabilize wounded warriors.
  • While cell therapy held promise in that arena, a lyophilized product that does not require ultra-cold storage is preferable.
  • The goal of the study was to determine the therapeutic potential of CDC-EVs in a rat model of acute traumatic coagulopathy induced by polytrauma and hemorrhagic shock.

Hybrid/Virtual/Decentralized Clinical Trials Market Outlook Report 2021: Hybrid Trial Use and Experience, Provider Selection, Provider Perceptions, Future Predictions, Study Data - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Nervous system, Branches of biology, Symptoms and signs, Acute pain, Nociception, Pain, Suffering

The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities.

Key Points: 
  • The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities.
  • The publisher surveyed 109 respondents at sponsors and CROs regarding their experiences with hybrid trials and providers of these services.
  • Though not all reported a smooth, pain-free experience, nearly two-thirds of respondents came away with a positive overall impression of hybrid trials.
  • 83% of respondents expect that the hybrid trial model will be used more frequently than the traditional trial model three years from now.

DentalPlans.com Advising Americans to Eat More Fruit This Summer

Retrieved on: 
Tuesday, August 3, 2021
Women, Parenting, Seniors, Children, Fitness & Nutrition, Dental, Family, General Health, Consumer, Health, Acute pain, Tooth decay, Chewing gum, DentalPlans.com, Henry Schein One, DENTALPLANS.COM, HENRY SCHEIN ONE

DentalPlans.com , a leading online marketplace for dental savings plans in the U.S. and part of the Henry Schein One portfolio of solutions, is advising Americans to keep their mouth and body hydrated by adding more fruit to their diet this summer.

Key Points: 
  • DentalPlans.com , a leading online marketplace for dental savings plans in the U.S. and part of the Henry Schein One portfolio of solutions, is advising Americans to keep their mouth and body hydrated by adding more fruit to their diet this summer.
  • A special health report from Harvard Medical School notes that a bodys basic systems function better when well-hydrated.
  • A dry mouth, on the other hand, can foster bacteria growth which can lead to dental decay and gum disease.
  • We are encouraging people to add more fruit to their diet to combat dehydration during hot, summer months.

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

Retrieved on: 
Monday, August 2, 2021
Nervous system, Branches of biology, Symptoms and signs, Acute pain, Pain, Nociception, Palliative care, Peripheral neuropathy, Neuropathic pain

The study, "An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat hind paw incision model," was designed to help assess the potential of SCI-160, the Company's proprietary compound.

Key Points: 
  • The study, "An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat hind paw incision model," was designed to help assess the potential of SCI-160, the Company's proprietary compound.
  • Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented, "We are thrilled by this report; the findings corroborate results of previous SCI-160 pre-clinical studies.
  • The global postoperative pain management market is expected to account for $45 billion by 2026.
  • In the first study, neuropathic pain reversal experiments, injections were administered on Day 7 after nerve injury.

New Analysis Shows iovera° Plays a Critical Role in Achieving Significant Reductions in Opioid Use, Pain Scores, and Hospital Stay Following Total Knee Arthroplasty

Retrieved on: 
Thursday, July 29, 2021
Medical specialties, Clinical medicine, Medicine, Acute pain, Prosthetics, Knee replacement, Opioid, Pain management, Arthroplasty, Pain, Manipulation under anesthesia

The results of the study, A Multimodal Pain Management Protocol Including Preoperative Cryoneurolysis for Total Knee Arthroplasty to Reduce Pain, Opioid Consumption, and Length of Stay, were published in Arthroplasty Today .

Key Points: 
  • The results of the study, A Multimodal Pain Management Protocol Including Preoperative Cryoneurolysis for Total Knee Arthroplasty to Reduce Pain, Opioid Consumption, and Length of Stay, were published in Arthroplasty Today .
  • This retrospective analysis utilized data from patients who underwent TKA by a single surgeon at one center.
  • Patients who received iovera before TKA were compared with a historical control group including patients who underwent TKA without iovera.
  • The primary outcome was opioid intake at various time points from hospital stay to 6 weeks after discharge.

Global Hernia Mesh Devices Industry (2020 to 2027) - Key Market Trends and Drivers - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Medical devices, Health, Acute pain, Hernia

The "Hernia Mesh Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hernia Mesh Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Hernia Mesh Devices estimated at US$4.2 Billion in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 3% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 4.7% CAGR
    The Hernia Mesh Devices market in the U.S. is estimated at US$1.1 Billion in the year 2020.
  • In the global Other Hernia Types segment, USA, Canada, Japan, China and Europe will drive the 2.4% CAGR estimated for this segment.

TIDI Products announces the addition of the AquaGuard line of moisture barrier products to its portfolio

Retrieved on: 
Thursday, July 29, 2021
Health, Acute pain, First aid, Injuries, Wound, Surgery, Barrier isolator, Patient safety

NEENAH, Wis., July 29, 2021 /PRNewswire/ -- TIDI Products, LLC, a leading provider of medical technology solutions including Sterile-Z, C-Armor, TIDIShield, and Posey, today announced the addition of the AquaGuard line of moisture barrier products to its portfolio of patient safety products.

Key Points: 
  • NEENAH, Wis., July 29, 2021 /PRNewswire/ -- TIDI Products, LLC, a leading provider of medical technology solutions including Sterile-Z, C-Armor, TIDIShield, and Posey, today announced the addition of the AquaGuard line of moisture barrier products to its portfolio of patient safety products.
  • AquaGuard's specialized products provide patients with crucial moisture protection for wound, surgical, and vascular access sites throughout the body when showering.
  • The addition of AquaGuard to the TIDI portfolio aligns with TIDI's purpose, 'Support Caregivers.
  • About TIDI Products, LLC TIDI Products has a history of providing forward-looking solutions to healthcare professionalssolutions that help reduce the risk of contamination and deliver the highest-quality patient care.

Dr. Trey Mouch Joins Central Texas Pain Center in Austin and Bee Cave

Retrieved on: 
Thursday, July 29, 2021
Pain, Nervous system, Branches of biology, Acute pain, Nociception, Pain management, Palliative care, Cancer pain

AUSTIN, Texas, July 29, 2021 /PRNewswire/ --Central Texas Pain Center is pleased to announce that Dr. Trey Mouch has joined the Central Texas Pain Center team after finishing his interventional pain fellowship at Weill Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Hospital for Special Surgery in New York.Dr.

Key Points: 
  • AUSTIN, Texas, July 29, 2021 /PRNewswire/ --Central Texas Pain Center is pleased to announce that Dr. Trey Mouch has joined the Central Texas Pain Center team after finishing his interventional pain fellowship at Weill Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Hospital for Special Surgery in New York.Dr.
  • Mouch will be providing patient care for Central Texas Pain Center in the rapidly growing Central and South Austin and Bee Cave neighborhoods of Austin, TX.
  • A native of Dallas, Texas, Dr. Mouch completed medical school at the University of Texas Health Science Center San Antonio.He has special interests in cancer pain, peripheral nerve therapies, and minimally invasive spinal therapy, including spinal cord stimulation and spinal decompression Therapies.
  • In addition, he firmly believes in a personalized and multidisciplinary approach to pain management to reduce patients' level of pain and increase their quality of life.

Global Dental Pain (Toothache Tooth Pain) Clinical Trials Review, H2 2021 Research Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Dental, Health, Branches of biology, Nervous system, Health sciences, Pain, Acute pain, Headaches, Clinical trial, Design of experiments, Pharmaceutical industry, Toothache

The "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" provides an overview of the Dental Pain (Toothache Tooth Pain) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Dental Pain (Toothache Tooth Pain).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Dental Pain (Toothache/Tooth Pain) to Central Nervous System Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Dental Pain (Toothache/Tooth Pain) to Central Nervous System Clinical Trials